-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Theravance Biopharma, Lowers Price Target to $15

Benzinga·03/04/2026 11:44:15
Listen to the news
HC Wainwright & Co. analyst Douglas Tsao maintains Theravance Biopharma (NASDAQ:TBPH) with a Buy and lowers the price target from $27 to $15.